65,437 trials
Peanut Allergy
Primary: Percentage of Treatment Responders at Month 12 — 67.0; 33.5; 52.4; 70.0 Percentage of participants — p=<0.001
Healthy
Primary: Number of Vaccines Administered by Participating Pharmacies in the Intervention and Non-intervention Communities Before and During the Intervention. — 3,093; 5,011…
Paroxysmal Atrial Fibrillation
Primary: Number of Participants With Acute Procedural Success — 30 Participants
Acetabular Fracture · Heterotopic Ossification
Primary: Number of Participants With Severe HO Formation — 3; 9 Participants
Depression · Anhedonia
Primary: Targeted Ventral Striatum to Ventromedial Prefrontal Cortex (VS-vmPFC) Connectivity — 0.183; 0.219; 0.275; 0.202 Mean subject-level FC Z scores
Insomnia · Sleep · Sleep Disturbance
Primary: Change in Sleep Architecture — 48.8; 54.0; 212.5; 218.7 Minutes
Lung Cancer · Non-small Cell Lung Cancer
Primary: Percentage of Participants With Best Overall Response (Best Overall Response Rate[ORR]) by 24 Weeks — 42.8; 47.6 percentage of participants
IDH1 Mutation · IDH2 Mutation · Recurrent Glioblastoma
Primary: Participants With Dose Limiting Toxicity (DLT) Rate Less Than or Equal to 33% (Dose Level 1) — 0; 7 Participants
Breast Cancer Female
Primary: Telehealth Usability Questionnaire (TUQ) — 6.38; 6.31 units on a scale
Advanced Solid Tumors
Primary: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Grief · Traumatic Stress · Usability
Primary: Traumatic Stress - Intrusion Subscale — 2.17; 1.93; 1.32 units on a scale — p=.083
Hearing Loss, Age-Related
Primary: Satisfaction With Social Participation — 49.7; 52.8; 51.2; 49.4 T-score — p=0.58
Erosive Osteoarthritis
Primary: CTX-I (C-terminal Telopeptide of Type I Collagen ) Bone Turnover Marker Levels — 0.05; 0.06; 0.63; 0.33 ng/ml — p=<0.01
Schizophrenia
Primary: Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score — -12.0; -12.3; -7.1 score on a scale
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 3; 3; 3; 3 Participants